Industry association · Spain · EU Transparency Register 025250318220-32
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Among the 1518 trade and business associations on this site, they rank #421 by legislative files engaged, a count of participation, not a measure of influence.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Farmaindustria in PolicySpeak: request access →
Work at Farmaindustria? so we know who speaks for it.
Farmaindustria filed 10 positions between 6 Jan 2021 and 13 Jul 2026, across 8 of the 665 legislative files tracked here, attaching a full position paper 1 time.
General public procurement legislation (Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC (Directive 2014/24)) has proven insufficient for the hospital public purchase of medicinal products, in particular for the purchase of innovative medicinal products subject to exclusive industrial property rights.
Filed in Spanish · English published by the European Commission
General public procurement legislation (Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC (Directive 2014/24) has proven insufficient for hospital public procurement of medicinal products, in particular for the purchase of innovative medicinal products subject to exclusive industrial property rights.
Filed in Spanish · English published by the European Commission
Farmaindustria (FI) supports the ultimate objective of the EC Proposal to improve the availability and access to medicines by promoting an innovative and competitive environment in the EU. We welcome the intention to prepare a regulatory framework for the future, maximising the use of fast-track procedures, optimising regulatory decision-making processes and reducing unnecessary red tape.
Filed in Spanish · English published by the European Commission
Farmaindustria considers it crucial to preserve the stability and predictability of the current European framework of incentives to attract investment and enable the pharmaceutical industry to continue to innovate in Europe, achieving better health outcomes.
Filed in Spanish · English published by the European Commission
Farmaindustria appreciates the Regulation for its potential to strengthen the EU’s competitiveness, strategic autonomy and innovation capacity, although it could be more ambitious in the face of increasing global competition and investment pressure from other regions.
Filed in Spanish · English published by the European Commission
Firstly, the Spanish National Pharmaceutical Industry Business Association (Farmaindustria) thanks the European Commission for opening the Inception Impact Assessment (IIA) on the forcing legislative proposal to create a European Health Data Space (EHDS). The necessary digital transformation of the health system has been highlighted during the recent COVID-19 crisis, with a strong boost to e-health solutions.
Filed in Spanish · English published by the European Commission
FARMAINDUSTRIA RESPONSE TO THE EC PRELIMINARY IMPACT ASSESSMENT OF THE ORPHAN AND PAEDIATRIC REGULATIONS Farmaindustria, which represents the innovative pharmaceutical industry in Spain, is committed to combating uncovered diseases by promoting research into new drugs and helping to ensure patients’ access to new treatments.
Filed in Spanish · English published by the European Commission
The EC proposal on the granting of compulsory licences (LO) is of great concern to FARMAINDUSTRIA by providing for the suspension of IP rights and preventing the choice of partners to voluntarily grant manufacturing licences for their products without any legal basis being observed to limit the use of this measure.
Filed in Spanish · English published by the European Commission
Farmaindustria, as the representative of the innovative pharmaceutical industry established in Spain, welcomes the proposed revision of the SPC Regulation of, given its objective of creating a harmonised and centralised approach to the application, evaluation and granting of SPC for both classical European and unitary patents (UPs), providing a clearer and more efficient framework for industrial property in the EU…
Filed in Spanish · English published by the European Commission
Making new therapies available to patients is a long, complex and risky process that requires considerable investment, giving industrial protection — and the period for which it is effective — a key role in embarking on this process.
Filed in Spanish · English published by the European Commission
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Farmaindustria next to another organization. Same files, same register facts, side by side. Compare →
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 289.
Everything on this page comes from Farmaindustria’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.